Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Rx Risk Needs To Be Shared By Government And Insurers – Humana

Executive Summary

Private health insurance companies would consider providing Medicare prescription drug plans if legislation provides for "risk corridors," or shared risk between the contractor and the government for drug costs, Humana's chief actuary said

You may also be interested in...

House Medicare Rx Bill Authorizes Tiered Co-Pays, De-Emphasizes Mail

The draft House Republican Medicare prescription drug bill includes language explicitly authorizing tiered co-pays

Medicare Rx Bills Unveiled: Does Provider Reimbursement Take Precedence?

The slim prospects for enactment of a Medicare outpatient prescription drug benefit have legislators eyeing the $350 bil. House budget set-aside as a source of enhanced provider reimbursements in 2002

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts